Hello and thank you for joining today's conference call to discuss Tilray Brands' Financial Results for the Fourth Quarter and Fiscal Year 2024 ended May 31, 2024. I will now turn the call over to Ms. Berrin Noorata, Tilray Brands' Chief Corporate Affairs and Communications Officer. Thank you. You may now begin.

Thank you, operator, and good afternoon, everyone. By now, you should have access to the earnings press release, which is available on the Investors section of the Tilray Brands website at tilray.com and has been filed with the SEC and SEDAR. Please note that during today's call, we will be referring to various non-GAAP financial measures that can provide useful information for investors. However, the presentation of this information is not intended to be considered in isolation or as a substitute for the financial information presented in accordance with GAAP. The earnings press release contains a reconciliation of each non-GAAP financial measure to the most comparable measure prepared in accordance with GAAP. In addition, we will be making numerous forward-looking statements during our remarks and in response to your questions. These statements are based on our current expectations and beliefs and involve known and unknown risks and uncertainties, which may prove to be incorrect. Actual results could differ materially from those described in the forward-looking statements. The text in our earnings press release includes many of the risks and uncertainties associated with such forward-looking statements. Today, we will be hearing from key members of our senior leadership team, beginning with Irwin D. Simon, Chairman and Chief Executive Officer, who will provide opening remarks and commentary; followed by Carl Merton, Chief Financial Officer, who will review our financial results for fiscal year 2024 and the fourth quarter. Also joining us for the question-and-answer segment are Denise Faltischek, Chief Strategy Officer and Head of International; Blair MacNeil, President of Tilray Canada; and Ty Gilmore, President of Tilray Beverages North America. And now I'd like to turn the call over to Tilray Brands' Chairman and CEO, Irwin D. Simon.

Thank you, Berrin, and good afternoon, everyone, and thank you for joining us today. Before diving into our fiscal 2024 results, I'd like to take a moment to reflect on the evolution of Tilray Brands. Back in 2019, Aphria was a cannabis-focused Canadian LP with only $50 million in revenue and minimal cash reserves. Since then, we've taken a strategic approach to diversifying our operations and growing our global businesses. Through a combination of organic growth and strategic acquisitions, we have disrupted the CPG industry by expanding our footprint into new markets and adjacent business categories. Today, Tilray Brands is a leading global lifestyle company, spearheading the conversion of cannabis, beverages, and wellness products and is elevating lives through moments of connection. We are operating in more than 20 countries across North America, Europe, Australia and Latin America, with five businesses in medical adult-use cannabis, beverages, spirits, wellness products, and 44 consumer connected lifestyle brands. As a vertically integrated company, we have 20 facilities that service our collective businesses allowing us to produce approximately 90% of our products internally, ensuring the high quality of our products. This is a testament to our success in building a diversified global business that is dedicated to providing the best possible products for our consumers. We're incredibly proud of the progress we've made in the short time and are excited to continue driving innovation and growth in the years ahead. Fiscal 2024 marked a year of significant accomplishments for Tilray Brands, achieving our best financial results to date. We achieved 26% net revenue growth with annual record net revenue of $789 million, record adjusted gross profit of $236 million, record adjusted EBITDA of $60.5 million, adjusted net income of $6.2 million, and positive adjusted free cash flow. We also strengthened our balance sheet by significantly reducing our net convertible debt by approximately $300 million, reducing our net debt-to-EBITDA ratio to 1.73x. We also exceeded our cost-saving synergy target by 31%, delivering $35 million of savings. Additionally, not only did we meet our revised annual guidance for adjusted EBITDA, but we also generated adjusted free cash flow of approximately $7 million for the year. Our record financial results were achieved despite the challenges we faced in the fiscal year, absorbing approximately $10 million in cannabis price compression, paying approximately $100 million in excise tax and regulatory fees in Canada, and paying higher operating insurance rates of nearly $7 million because of our cannabis businesses, which together equate to approximately $120 million that directly impacted our bottom line. Our ability to deliver record financial results while navigating these challenges is a testament to the resilience and dedication of our team who have worked tirelessly to ensure the success of our businesses. Over the past fiscal year, our strategic acquisitions have significantly benefited our financial results, which we expect will continue to benefit us well into the future. In June 2023, we acquired HEXO and Redecan to expand our cannabis business, our productions, capability, and brand growth and opportunities in Canada and internationally. Since then, we have broadened Tilray's cannabis product portfolio across multiple form factors, including an 85% year-over-year increase in mainstream flower sales in adult-use cannabis. The addition of Redecan brand has further strengthened our categories such as pre-rolls, oils, and capsules. Today, Tilray is the number one player in the straight edge pre-rolled category with a 46% market share and a top player in the oils and capsules category combined with a 21.5% market share in the adult-use business in Canada. In August 2023, we acquired Truss Beverages, fortifying Tilray's leadership in the Canadian cannabis beverage market. This acquisition increased our market share in the beverage category by 400%, growing our market share in the THC beverage category to 41% at the end of fiscal year 2024. In September 2023, we acquired eight iconic beer and beverage brands from ABI, along with related breweries and group hubs. As a result, we're now the fifth largest craft brewer in the U.S., with a 4.5% share of the craft beer market. Our growing beverage portfolio now includes craft beers, spirits, ready-to-drink cocktails, ciders, and non-alcoholic beverages. The combination of our legacy businesses and these acquisitions resulted in our best fiscal year results. Let's now dive deeper into each of our business segments. Tilray Cannabis, global cannabis net revenue increased by 24% during fiscal 2024. In Canada, our quarter four marked the culmination of a transformative year in Canadian cannabis. It was the highest revenue quarter of the year at $58.8 million and marked the completion of our HEXO and Truss Beverages integration, a significant operational overhaul resulting in extensive improvements in our facility utilization. We continue to lead Canadian cannabis market share by almost 200 bps over the next competitor and have consistently been at the top of the industry for the past three years. From a regional perspective, Tilray was number one across British Columbia, Alberta, Ontario, and Quebec provinces combined, which include over 80% of the Canadian population, and we've also led in all secondary markets. In Canadian cannabis volume, Tilray shipped approximately 60% more in kilograms, reaching 140 metric tons. Our unit sales grew approximately 130% to almost 35 million units. In fiscal 2024, approximately 27% of our Canadian adult-use cannabis net sales revenue came from new innovation, which is a testament to our successful ability to innovate and launch new products. Cannabis consumers have a unique attribute of being open to trying new products. And in fiscal 2024, we capitalized on this by launching over 150 new SKUs. Looking ahead to next year, we anticipate that innovation will continue to play a significant role in driving our net sales, with brands such as Broken Coast, Redecan, XMG, Mollo, and Good Supply launching exciting new products based on feedback from our consumers and our bartenders. Our strategic acquisition of HEXO and Redecan aims to integrate their sales plan into our infrastructure and expand our brand portfolio and product mix. In fiscal '24, we almost doubled the Redecan flower share with the launch of three popular genetics: Animal RNTZ, Space Age Cake, and Purple Churro. In Ontario, Animal RNTZ became the number one selling genetic for both 14g and 3.5g pack types, respectively. Space Age Cake was number eight in the 14g flower segment, despite limited availability. In fiscal '25, we expect these genetics to continue to be among the top 10 performing genetics in the mainstream flower. In 2024, we made significant steps to rightsize our operational footprint in Canada to balance supply and demand. We sold the Truss facility and transitioned all our cannabis beverage production to our London, Ontario drinks facility, pushing the London facility's utilization above 70% and improving our cannabis gross margins. These cannabis beverages are phenomenal. I wish we could sell them in the U.S. today. We centralized all our HEXO brand packaging and logistics into Leamington, Ontario, lowering our labor cost per unit by 35% and delivering $35.4 million in synergies and exceeding our initial target of $27 million by 31%. We successfully transitioned our Broken Coast cultivation to our Nanaimo, B.C. facility, increasing yields by 30% and lowering our cost per gram by 15%. We also paused the growing at our Cayuga facility this year, which will drive additional savings of $4.5 million on an annual basis. Finally, we transitioned a large portion of our Quebec cultivation facilities to vegetables, which we expect will contribute over $5 million annually to offset the cost of the facility, improving the marketability and value of the facility, while continuing to grow cannabis in smaller portions of the facility to meet the needs we want for our Quebec consumers. All of these initiatives were designed to significantly lower the cost of growth, manufacture, package, and ship our leading cannabis brands to market. These consumer and operational initiatives are entirely leveragable in markets around the world for years to come. In fact, early in fiscal '25, we shared significant learnings in cultivation and genetics with our teams in Europe. Turning to our international cannabis, we grew net revenue by 22% year-over-year to approximately $53 million and remained the number one market leader in medical cannabis across Europe. Our annual growth during the fiscal 2024 was driven by increased sales in Germany, Poland, the U.K., Australia, and New Zealand. In Germany, we believe we're best positioned to capture a majority of the expected incremental growth in the cannabis medical market, which is projected to be approximately $3 billion in the medium term. On April 1, the Cannabis Act became effective in Germany, which declassified cannabis as a non-narcotic, expanding Tilray's market opportunity in Germany. Since the Cannabis Act went into effect, we have already seen a 65% increase in sales, and we believe that our current positioning in Germany provides us with several unique competitive advantages. Our cultivation facilities in Germany and Portugal, combined with our Tilray Pharma medical distribution network, provide Tilray with critical vertical integration, allowing us to consistently supply the market with high quality and a reliable source of medical cannabis. Aphria RX was the first facility in Germany to receive both its cannabis cultivation license and commercial distribution license for medical cannabis under the new regulations, allowing Tilray to cultivate, produce, and distribute premium quality medical cannabis, increasing its production by 5x. Aphria RX can now fully utilize and maximize its growing capacity while expanding its genetics to a total of 31 approved strains from the previously approved three strains. We believe that this, coupled with the steps being taken by Germany to liberalize the reimbursement of medical cannabis, significantly increases the opportunity in the German market. We believe that Germany's declassification of cannabis as a non-narcotic will also have a far-reaching impact on drug policy throughout Europe. The European opportunity could represent a potential $45 billion medical market alone over the long term, and our presence in Europe allows Tilray to grow our global brand portfolio to a base of 700 million people, which is twice the population of the U.S. Turning to another promising international market, this fiscal year, we launched Broken Coast medical cannabis products in Australia. Medical cannabis patients in Australia now have access to Broken Coast through our cannabis strains cultivated from our facility in Canada. This launch came in response to the feedback we received in Australia and leveraged our insights from our operations in Canada and Europe. Now briefly, on our CC Pharma, Tilray Pharma distribution business in Germany, which represents our medical cannabis business through its network of 13,000 pharmacies, CC Pharma revenue was nearly flat at $259 million, both in fiscal 2024 and fiscal 2023, but our gross margin held at 11% during both periods, but may fluctuate with changes in product mixes as we focus on higher-margin sales in future periods. Moving on to Tilray Beverages. In the U.S., we operate the fifth largest craft brewery by sales with six manufacturing facilities, over 500 distributors, 11 brew hubs, and one distillery restaurant along with a sales and marketing team across the country. Our Tilray beverage strategy focuses on growing our portfolio of iconic craft brands, ensuring product excellence and innovation, driving scale, and expanding distribution to increase market reach and consumer access. In our beverage segment, we generated $200 million in fiscal 2024. On an annualized basis, we'll quickly approach $300 million as we ramp up. Across our growing brands, SweetWater remains the number one brand family in Georgia, multi-outlet. Montauk remains the number one brand family in Metro New York, having increased its distribution by 570 basis points over last year. Tilray is now the number one craft supplier year-to-date in the Pacific Northwest. 10 Barrel's volume growth increased by 640 basis points since Tilray took over the brand, and we're capitalizing on the success of 10 Barrel's Pub Beer brand extension with Pub Ice and the Pub Cerveza line extension. Both innovations have performed extremely well in the market with 4,200 new distribution points, growing 18%. Pub Beer is now the 11th largest brand on the West Coast with only half the distribution of top competitors due to its focus on the Pacific Northwest states. Since Tilray acquired Shock Top in 2023, we have made significant progress in turning the brand around. In just eight months, we have cut total Shock Top declines in half, and our top 10 distributors have shown a remarkable 35 basis point improvement. As a result, Shock Top finished quarter four with 13.5% growth year-over-year since we acquired the brand, a testament to our team's hard work and commitment to delivering outstanding results. We're excited to continue building on this momentum and driving growth for Shock Top in the years ahead. As we have mentioned before, our vision extends far beyond our current reach as we focus on becoming a dominant leading beverage business by leveraging our portfolio of beloved local craft brands to win more hearts and occasions, and bring these brands back to growth with innovation into new categories, including our non-alcoholic beers, flavored malt beverages, ready-to-drink cocktails, spirits, and beyond alcohol as we expand further into water, energy drinks, and other categories. We have the manufacturing facilities, distribution, and sales and marketing infrastructure to drive growth in Tilray's beverage businesses. In the Non-Alcoholic segment, we launched a new brand, Runner's High Brewing Company. For those who love remarkable beer flavor without the buzz, this brand seeks to be the beer of choice for runners and their community, not just elite athletes. There are currently three brews: Runner's High Golden, Wheat, Raspberry Wheat, and Dark Chocolate, with several expansion markets to follow. In April, we celebrated high honors and awards at the 2024 Craft Brewer Conference and the World Beer Cup. 10 Barrel Brewing won four craft beer awards, and the 10 Barrel Brewmaster was recognized for innovation in craft brewing. I'm incredibly proud of the Tilray Beverages' team for these outstanding achievements. With over 500 beer and beverage distributors, Tilray is now a leading supplier in key regions across the U.S. with regional jewels in the Northeast, Pacific Northwest, Colorado, and Southeast. Per BI shipments for retail, Tilray has increased its market share of total craft beer in seven states, including key markets such as Oregon, Washington, Florida, Colorado, and Arizona, when comparing shares after the acquisition of our eight craft brands. With each beverage acquisition we've made over the past few years, we have optimized our cost structure, improved operational efficiencies, and brought these back to our beloved brand for growth. As we complete our integration process, we expect to achieve the margin of these eight craft brands similar to the gross margin shared by SweetWater and our other legacy businesses. We also relaunched HiBall Energy Drinks on Amazon and plan to launch new hemp-derived Delta-9 beverages strategically in selected markets, including Texas and New Jersey, where we can leverage our existing beverage distribution network. Our hemp-derived Delta-9 formulations are complete, and we're actively developing a launch strategy to ensure maximum impact. We look forward to sharing more updates on this exciting development soon. With our operational strength, Tilray is on a path to become a lightning rod for the beverage industry, rejuvenating growth in these brands. In Tilray's spirits, Breckenridge Distillery continues to win accolades as the best American whiskey for two years in a row and is now one of the most awarded craft distilleries in the U.S. In addition to its award-winning Bourbon, Breckenridge Distillery also produces highly coveted gin and vodka. Finally, let's discuss our Tilray Wellness businesses' focus on improving people's lives through the power of hemp. Tilray Wellness is represented mainly by Manitoba Harvest, our leading hemp brand, with over a 53% market share in branded hemp products, Happy Flower, CBD-infused beverages, and HiBall Energy Drinks. In quarter four, our Tilray Wellness business saw impressive growth, with a 6% increase in revenue to $15.7 million. For fiscal 2024, the business generated 5% growth, bringing in $55.3 million, with stable improvements to gross margins of 30% from 29% last year. Tilray Wellness strengthened its leading market share positions in both the U.S. and Canada over the past year, with consumption increasing in both natural and conventional channels. As Tilray Brands has transformed, expanded, and completed numerous acquisitions to get to where we are today, our mission has evolved to become a leading premium lifestyle company with a house of brands, innovative products that inspire joy, wellness, and create memorable experiences. With that, I'll now turn the call over to Carl, to discuss our financial results in greater detail. Carl?

Thank you, Irwin. I'll begin with a brief overview of our annual results for fiscal 2024, before moving on to a more in-depth review of Q4. Note that we present our financials in accordance with U.S. GAAP and in U.S. dollars. Throughout our discussion, we will refer to both GAAP and non-GAAP adjusted results, and we encourage you to review the reconciliation contained within our press release of our reported results under GAAP with the corresponding non-GAAP measures. Net revenue for fiscal 2024 grew 26% to $788.9 million, compared to the prior year at $627.1 million, which, as Irwin stated, was a record outcome. By segment, beverage alcohol revenue increased 113%, largely attributed to the acquired brands. Cannabis net revenue rose 24% year-over-year, inclusive of $9.8 million due to price compression in Canada, of which nearly all represented a reduction in EBITDA. Distribution net revenue was flat, and wellness net revenue rose 5% for the year. From a segment perspective, 25% of our net revenue was generated by our beverage alcohol business, 35% was generated by our cannabis business, 33% by our distribution business, and 7% by our wellness business. This compares to 15% beverage alcohol, 35% cannabis, 41% distribution, and 9% wellness last fiscal year. The year-over-year variance is due to our acquisition of HEXO, the new craft brands, and the remainder of the Truss Beverage brands. Further, as we progress through a full year with the new beverage alcohol brands, we anticipate these ratios to converge around 30% beverage alcohol, 30% cannabis, 30% distribution, and 10% wellness. Gross profit for fiscal 2024 increased 52% to $223.4 million, another record, compared to the prior year at $147 million. Gross margin increased to 28% from 23% in the prior year. Adjusted gross profit increased 14% to $235.6 million from $206.4 million in the prior year, while adjusted gross margin declined by 300 basis points to 30%, primarily reflecting the removal of the HEXO advisory service revenue in the prior year, with their initially lowered margins, and the impact from the recently acquired craft brands. By segment, beverage alcohol gross margin was 44%, compared to 49% in the prior year, due to lower cost margin contributions from the craft acquisitions, resulting from temporary excess capacity that we are in the process of optimizing and enhancing. Beverage alcohol adjusted gross margin was 46%, compared to 53%. This was offset by a $2.5 million volume commitment reimbursement in our spirits business, with no associated costs. For greater context, adjusted gross margin for our legacy beverage business was 58%, compared to the prior year of 53%, primarily as a result of an agreement with the distributor related to our spirits business and more volume flowing through the facilities as we ramped up production in March and April to meet strong seasonal demand in April and May sales. Adjusted gross margin for the newly acquired craft brands was 33%. The improvement of gross margins in beverage alcohol, primarily in the beer portion of our business, as Irwin said earlier, is a major focus of ours, and we should begin to demonstrate improvements in Q1 of fiscal 2025. As of the end of our fiscal year, we successfully integrated production of all the acquired brands into our production facilities and exited their related co-manufacturing agreements with the exception of Shock Top. As a result of this production integration, we will no longer separate the gross margins between legacy products and the new craft products starting next quarter. Cannabis gross margin was 33% compared to 26% in the prior year. An adjusted gross margin was 36%, compared to 51%, primarily due to the termination of the HEXO advisory services agreement, which contributed only $1.5 million of gross profit in the current year compared to $40.4 million in the prior year. We also experienced a change in sales mix, with a higher percentage of sales coming from wholesale, compounded by the price compression in the Canadian adult-use market, as I will explain in further detail shortly. Distribution gross margin held steady at 11%, although it was expected to improve with changes in product mix as we focus on higher margin sales in future periods. Wellness adjusted gross margin was up slightly at 30%, compared to 29%, driven by lower material costs and overhead optimization. Net loss for fiscal 2024 improved to $222.4 million, or $0.33 per share, compared to $1.4 billion in the prior year, or $2.35 per share, with the latter tied to non-cash goodwill impairment in the prior year. From an adjusted perspective, we are reporting adjusted net income of $6.1 million, or $0.01 per share, compared to $0.4 million, or $0.0 per share, in the prior year. Under the current year's adjusted EBITDA definition, fiscal 2024 improved to a record $60.5 million, up 3% from $58.7 million in the prior year. Under the prior year's definition, we would have reported adjusted EBITDA of $65.1 million in the current year while reporting $61.5 million in the prior year. We have now generated positive adjusted EBITDA for five consecutive years. Cash flow used in operations was $30.9 million, compared to $7.9 million of cash generated by operations in the prior year. Adjusted free cash flow was $6.6 million for the year, which we view as a very positive outcome, considering that just last quarter we had communicated that we did not believe we would achieve our goal of reaching positive free cash flow in fiscal 2024, but we expected a very strong Q4 that proved to be stronger than we had anticipated. Over this past year, we reduced our convertible debt by almost $300 million, decreasing our net debt to approximately $61.3 million and leaving us with a net debt to EBITDA ratio of 1.73. Our intention is to continue lowering our indebtedness, optimizing our capital structure, and enhancing our financial flexibility. The net reduction in our convertible debt will decrease our annual interest expense by $14.4 million, which flows directly to net income and free cash flow. Let's now review our quarterly performance. Q4 total net revenue rose by $45.7 million to $229.9 million, compared to the prior year quarter of $184.2 million, representing almost 25% growth. The diversification of our business through our adjacency model really came into play during Q2. For the first time, our beverage alcohol segment exceeded the size of our cannabis segment in Q4, representing 33% of our total revenue mix, compared to only 18% for Q4 during the previous fiscal year. In Q4, compared to the prior year period, net beverage alcohol revenues rose 137% to $76.7 million. Net cannabis revenue rose 12% to $71.9 million. Distribution revenue decreased 10% to $65.6 million, and finally, wellness revenue rose 6% to $15.7 million. We are disappointed that the Canadian government did not resolve the issue of cannabis excise taxes during their last budget and maintain our view that reform is essential to the long-term viability of the Canadian cannabis industry. The current fixed price tax structure is inherently unfair, as it has allowed taxes as a percentage of revenue to spike even as the price of cannabis has declined by more than 50% since legalization. Still, as Irwin mentioned, as a result, we paid over $100 million in excise taxes last year and will continue to do so every year in the future until it changes. We are encouraged that CRA is beginning to crack down on delinquent LPs, asserting cash flow pressures on our less financially strong competitors, potentially forcing an industry-needed LP rationalization. We incurred $22.1 million in Canadian cannabis excise taxes during Q4, which are a reduction to revenue, compared to $16.4 million last year. However, due to a change in our revenue mix to higher excise tax products, and without the advisory fee, which is not taxed, the excise tax amounted to 33% of gross Canadian cannabis revenue, excluding wholesale in Q4, compared to 25% in the same quarter last year. Gross profit was $82.4 million, compared to $67.2 million in the prior year quarter. Gross margin remained consistent at 36%, while adjusted gross margin decreased 100 basis points to 36% compared to the prior year quarter. Most of the variance was related to cannabis, which included significantly higher HEXO advisory fees in the prior year, along with higher sales from wholesale and price compression in the Canadian adult-use market in the current year. Net loss improved to $15.4 million, compared to a net loss of $119.8 million in the prior year quarter. On a per-share basis, this amounted to a net loss of $0.04 per share versus $0.15 per share in the prior year quarter. Adjusted net income in the quarter was $35.1 million, which when calculated on a per-share basis, resulted in an adjusted EPS of $0.04 for the quarter, a $0.06 improvement from the prior year quarter. Adjusted EBITDA was $29.5 million, up 37% from $21.5 million in the prior year quarter, representing a new record level of quarterly adjusted EBITDA. On synergies and cost reductions, recall that our revised HEXO synergy plan targeted between $30 million and $35 million in savings. We exceeded that by achieving $35.4 million of savings on an annualized run rate basis, of which $26.2 million represented actual cost savings during the year. Operating cash flow was $30.7 million, compared to $43.6 million in the prior year quarter. This decrease in operating cash flow is primarily a function of restructuring in HEXO exit costs, as we complete the integration of HEXO's operations into ours. Adjusted free cash flow was $30.6 million, compared to $48.3 million in the prior year quarter, consistent with the changes in operating cash flow. Turning now to our four business segments, beverage alcohol revenue was $76.7 million, up 137% from $32.4 million in the prior year quarter. The positive delta was due to contributions from the craft brands purchased last fall—a strong beer business leading up to the summer, which is a historically busy season—and new innovations across the portfolio launched as part of the spring reset. Beverage alcohol gross profit increased to $40.8 million, compared to $16.6 million. Adjusted gross profit increased to $41 million, compared to $17.8 million. While beverage alcohol gross margin increased to 53%, compared to 51%, and adjusted gross margin decreased to 53%, from 55% in the prior year quarter. Gross cannabis revenue of $94 million was comprised of $61.5 million in Canadian adult-use revenue, $13.1 million in international cannabis revenue, $6.4 million in Canadian medical cannabis revenue, and $13 million in wholesale revenue. Net cannabis revenue, which excludes $22.1 million in excise taxes, was $71.9 million, representing a 12% increase from the year-ago period. The positive variances relate to increased organic growth, excluding the HEXO advisory fee, combined with contributions from the acquisition of HEXO and Truss. Offsetting the increase in net cannabis revenue was the elimination of advisory services revenue, totaling $16.1 million from the prior year quarter due to the HEXO acquisition, which terminated the previous strategic arrangement that was in place. Revenue from Canadian medical cannabis grew 6%, despite the category being impacted by competition from the adult-use market and its related price compression. Wholesale revenue increased to $13 million from $0.8 million last year. The Canadian cannabis industry is currently experiencing an interesting, previously unexperienced phenomenon that we took advantage of in the current quarter. As many in the industry moved to asset-light business models, a significant portion of previous production capacity has disappeared. This, in turn, has resulted in previous excess inventory levels in the industry dissipating. With lower inventory levels, securing supply appears to have become more difficult, and pricing in the wholesale market is increasing, as much as 5x in some product categories. Against this new backdrop, we took advantage of advantageous pricing in the quarter, resulting in a significant increase in our wholesale revenue. While opportunities related to wholesale product demand from asset-light Canadian LPs are expected to remain in the short term, we do not anticipate this level of quarterly wholesale revenues to become the new norm. International cannabis net revenue was $13.1 million in the quarter, compared to $15.7 million in the prior year due to timing differences of shipments in the international markets to various countries. Cannabis gross profit was $28.8 million, and cannabis gross margin was 40%, compared to $39.5 million and 61% in the prior year quarter. Distribution revenue, derived predominantly through Tilray Pharma, decreased to $65.6 million from $72.6 million in the prior year quarter. Distribution gross profit increased to $7.8 million, compared to $6.7 million in the prior year quarter, while distribution gross margin increased to 12%, from 9% in the prior year quarter, driven by our increased focus on margin. Wellness revenue grew 6% to $15.7 million from $14.8 million in the prior year quarter. Wellness gross profit was $4.9 million, up from $4.4 million in the prior year quarter, and gross margin rose to 31%, compared to 30%. Our cash and marketable securities balance as of May 31 was $260.5 million, down from $448.5 million in the year-ago period. The majority of the variance was related to the repayment of the Tilray '23s, the cash purchase price of our acquisition of the craft brands, and settling assumed liabilities and exit costs from HEXO, including the unpaid excise tax we inherited as part of this transaction, as well as legacy litigation settlements. Fiscal 2024 was a year marked by major acquisitions in both the beverage alcohol and cannabis segments. In addition to the revenue increases we enjoyed from these acquisitions, we also made significant progress in integrating those acquisitions into our existing infrastructure. For the cannabis segment, this integration is largely complete, with redundant assets available for sale, the largest pieces remaining in our integration plan. For the beverage alcohol segment, there is still work to be done on the integration. As I said previously, all brands except for Shock Top have exited their co-manufacturing agreements and are now being produced in our facilities. Our integration work will continue to ensure we are maximizing low-cost production footprints and their related utilizations, fully integrating purchasing decisions across all brands to take advantage of pricing commensurate with our status as the fifth largest craft producer in the U.S., and fine-tuning all our production activities, all to bring our consolidated beverage alcohol margins back up above 40%. Finally, we are pleased to provide the following guidance for fiscal 2025. We anticipate net revenues to be between $950 million and $1 billion, with mid-single-digit organic growth. Let me now conclude our prepared remarks and open the lines for questions from our covering analysts. Operator, what's the first question?

Thank you. Our first question is from Robert Moskow from TD Cowen. Your line is now live.

Hi, thanks for the question. I believe you normally give EBITDA guidance. I'm kind of new to the story. So can you tell me whether—what was the decision regarding EBITDA guidance for fiscal 2025?

I think—from anything drove it, but I think sales and as a growth company, it's based around revenue, but our cash flow, our free cash flow. And I think as we've outlaid where our goals are to get to margins, I think, Robert, you're a pretty smart analyst, I think EBITDA is something we can figure out. And I think as a growing company and things happen, but I think it all starts in the sales number and it all starts on the organic growth number. And the rest runs back through the P&L. That's why no other reason why.

While you used to give it, and now you've decided to not provide that range going forward?

I think we give the sales, we give our organic growth, and we give expectations on where our margin is. I think the rest can usually flow through the P&L.

Okay. Can you give us a little kind of step-by-step status on - for the next 12 months towards integrating your ABI brands and how the gross margins will improve, like what needs to happen next?

Well, I think number one, it starts with these brands starting to grow again. And some of the examples we showed is what's happening with Shock Top, what was happening with some of the 10 Barrel, so that's number one. We put a lot of innovation out there and getting that innovation out there, and we've seen some great results so far from that. As we look today at our manufacturing facility and heard what I said before, 90% of our products are made in our own facilities. So ABI was doing some of our manufacturing, and how do we bring more of that manufacturing into our facilities? Our prior gross margin at SweetWater was in the high 40s, low 50s, so how do we get some more efficiencies in purchasing and some of the production standpoint? So that is number one. Number two is we have 500 distributors out there. And some excellent distributors that came along with the ABI, some excellent distributors. Are there some consolidation opportunities there? And all these distributors are looking for more business, so how do we grow with them? So that is the big thing. Also, we're looking at some international opportunities where we could grow our business internationally. So that's the big thing. And you come back and look at it today, where these margins were when we bought them and where our legacy margins are? And that is a big focus. Last week was our strategic planning meetings, and that's our big focus. If you can grow our gross margins by a few points, that's a lot of dollars dropping to the bottom line. And you heard Carl talk about giving guidance in regards to high to mid-single organic growth, plus the acquisition growth, that's pretty good growth out there where the beer category is not growing at all. And if we can get a few points on the gross margin, there's a lot of money that drops to the bottom line here.

Okay. Thank you very much.

And the big thing is, when we went out and did our first acquisition of beer, we're selling 2.5 million cases. We're going to sell 12 million, 13 million cases of beer next year, so there's a lot there of costs that we can take out.

Thank you. Next question is coming from Andrew Carter from Stifel. Your line is now live.

Hi, thanks. Just want to get back to the EBITDA kind of thinking about you came in at seven, eight kind of EBITDA margin this year. Your growth for next year kind of putting you in incremental $162 million to $200 million. Could you—how should we think about incrementals? Does the EBITDA margin expand from here? Just anything directionally? And then I'll just—I'll tie this all into one question. As far as the free cash flow outlook goes, I don't know if you gave CapEx, could you give that? How should we think about working capital this year? And anything else that should the free cash flow grow from here? Thanks.

So just—and I'll turn it over to Carl, too. Just on the EBITDA margin, first of all, as you heard me say before, when we acquired these businesses, it was pretty low in regards to where the gross margin looks. They were not integrated, and there's a lot of costs that we have taken out. And you heard what I said before on the HEXO business, we've taken out over $31 million, $32 million in regards to cost savings on HEXO. So today, as a company and as we gave sales guidance between $950 million to $1 billion and as we add on to that top line organic growth plus acquisition growth, get those margins, there's a lot more that, Andrew, that drops to the bottom line that goes into your EBITDA margin. And listen, I come back and you heard what I said in my script. We expect that there would be some relief in regards to excise tax it's not going—not happening. So between excise tax at $100 million, paying much higher costs for insurance because of our cannabis business, and much higher costs of some of our legacy licenses that we have with IT. We're digesting well over $100 million just of cost and price compression, which over the last few years has been over $200 million. So, we're digesting a lot of these costs within our P&L, but we're taking a lot of costs out of our business, and we're also getting a lot of organic growth to offset that. Carl?

Just on CapEx, we spent about $30 million this year on CapEx. We spent a little over $20 million the year before. CapEx for next year will be right in that range. As it relates to working capital, we don't see the need to grow the working capital from where we're at today over the next year.

So—and just on that, we spent between CapEx. We spent it on Masson in conversion there. We sell over $6.5 million in regards to our SweetWater facility. We spent some other CapEx in some of our other facilities. So with that, we got some pretty efficient facilities and pretty— a lot of CapEx that could expand. So, we don't expect to spend a lot of CapEx going into next year—into this year.

I guess just one more question on kind of the - you mentioned the $10 million headwind to EBITDA this year from price compression. If you had to kind of like straight-line pricing at this point, would—where would the headwind be to EBITDA next year from pricing? And as you mentioned the innovation, are you able to—is the innovation accretive from a pricing perspective, therefore, less excise tax or gross margin accretive, whatever you want to call it? Is it accretive to your cannabis growth? Thanks.

So, I hate to tell you, there's no relief on excise tax, just to be clear to everybody on this call; excise tax is a fixed amount where you're paying $1 a gram. If the prices keep coming down 20%, 30%, 40%, you're still paying excise tax. As a matter of fact, as a percentage, our excise tax as a percentage of sale keeps going up. So just remember, our price compression over the last couple of years has been about $200-plus million. If that never happened, that would just ultimately be your cost of goods that drops to your bottom line. So with that, we feel good. And you heard what Carl said in regards to other LPs not being able to pay excise tax in the Canadian government going after them and forcing them away. So number one, we feel good that pricing now basically has flattened out. And if anything, we're looking to get some price increases, and the question you asked about some of the new innovations that we're coming out with is unique to what Tilray can do. And hopefully, we can get higher prices for them. So, hopefully, we're not going to see anywhere near the price compression we have seen over the last couple of years, Andrew.

Thanks. I'll pass it on.

Just to give some…

Go ahead, Carl.

Just to give some cadence on that through the year. We were looking at about $3 million a quarter, up until the fourth quarter. I mean we did not see any price compression in Q4.

Thank you. Our next question is coming from Aaron Grey from Alliance Global Partners. Your line is now live.

Hi, good evening, and thank you for the question. So first question from me, I want to talk a bit about Germany since the law changed there. I believe you mentioned a 65% increase since April 1. So just wanted to clarify, was that specifically for increase in the quarter? Or will you see it today relative to before the change? And then just any further commentary you can provide? I know you talked about your own production increases, buybacks domestically, and you have Portugal as well. But anything you're seeing overall within the market in terms of scripts, are you seeing some bottlenecks that are maybe keeping the market from growing even faster, than it could? So just your overall sense in terms of, how you're seeing the market evolve there? Thank you.

Thank you. I'm going to let Denise answer that question.

Thanks, Irwin, and thanks for the question. So in terms of your first question about the 65% growth, given that we're reporting on the end of the fiscal year as of May 31, this is a number that reflects basically our Q4 growth from the April 1 adoption of the new regulations. And then second, in terms of the bottlenecks and potential challenges we're seeing in the marketplace. One of the things we are seeing is, in fact, the German government is becoming overwhelmed with the import and export permits, the import permits into Germany. We've been hearing basically given some of the increased demand on medical cannabis in terms of increasing patients and increasing number of prescriptions, we have in fact seen the permit timing going from two weeks to six weeks. The other thing that we're seeing is in terms of the ability to fill prescriptions very quickly given the increased demand. So those are the two bottlenecks that we see. And I think both are more short-term. As the aspects of the supply chain, when we import from the German government, and then fulfillment of prescription start to level out as more resources align against those. So, I do see them as temporary measures in terms of restrictions on growth.

Okay. Great. Thank you very much for that color there. And then second quick one from me, just on the hemp-derived Delta-9 beverages that you mentioned again on this call. Formulations are complete. You mentioned some—you're going to do it state-by-state. I believe you mentioned Texas and New Jersey as two of the states. So just any commentary on how many states you believe right now you'd be able to sell into? And then how the conversations you're having with some of your distributors, both larger and smaller, in terms of the desire for these hemp-derived beverages. Have you seen the desire increase, especially their ability to participate with someone who is an existing player like you guys with alcohol beverages? So how are you seeing the overall demand for the Delta-9 beverages? And how many markets do you think you're going to build into within the current environment? Thanks.

So number one, you heard me say before, and I wouldn't put a dollar value on it, but if we could sell our THC beverages that we produce in Canada today in the U.S., it would be a large-sized business for us if we could ever do that. With that, we can't—as we can't sell anything that are THC-infused products. We're looking, and you heard me mention the states we're looking at, and I will tell you this year. There is a lot of our beer distributors that have reached out to us and want the product right away because they have seen in markets where it is how well the sales are doing. So, we'll look at rolling it out online in some markets. And the markets we feel we can do it and do it legally, we do it right. There's about three or four markets that we would do right away. We do have the products—we do have the product that has been developed. We have the formulations. We don't have products out there today, but we do have the formulations. We do have the product ultimately ready to go once we get the go-ahead and clarify our plans.

Okay. Great. Thanks for the color and I'll jump back into the queue.

Thank you.

Thank you. Our next question today is coming from Owen Bennett from Jefferies. Your line is now live.

Afternoon guys, hope all is well. And I just had a couple of questions on beverages. The first one, on energy drinks, obviously, a very attractive category, but also very competitive. I was just wondering how you're thinking about what you think you need to do to be successful in that category? And will the focus be on HiBall? Or are you planning to launch additional brands as well? That's the first one? Thanks.

So I think—and again, to clarify, the focus is beyond our beverages. Was that what you're asking and what beverages, what brands within our beverage business?

No, no, sorry, you didn't hear me. It was on the energy drinks specifically.

On energy drinks…

Yes, very attractive but very competitive. What do you think you need to be successful in that category? Will it just be HiBall or additional brands beyond HiBall?

Okay. Okay. Okay. I got you, Owen. Sorry about that. So Owen, I got to tell you, in my career, I've received many requests from consumers. I've never had so many requests for consumers on HiBall when ABI discontinued the product. So there will be a big focus on our HiBall product. We come out with a water product called Liquid Love. We tested in the marketplace with some very, very high results and good results on that. Our non-alcoholic beers, if I was to put that in a glass and even you, who know beer, ultimately, I'm not sure you know the difference between that and a regular beer. So we've come out with some good energy drinks. We've come out with some great non-alcohol beers. We've come out with some water drinks with Liquid Love, both in sparkling and still in multiple flavors. So far, the demand from our distributors in those and our consumers has been strong. But we'll continue to push out the innovation that we have put forth in regards to some of the stuff that we've come out with Montauk, some of the SweetWater, and some of the 10 Barrels, some of the new flavors that we've come out with Shock Top, or some of the exciting things. So, we see tremendous growth and tremendous potential in some of the brands that we acquired, returning to growth where they were declining.

Okay. Sounds fair. And then just one quick follow-up on Aaron's question on THC. Are you planning to sell this by e-commerce as well so you can get international?

Yes. Like I said before, on Delta-9, it's something that we're going to focus on, and we will sell it in e-commerce, but we will also sell it into retail through beer distributors that are all in agreement and can take it in retail markets that we can sell it. So far, we've had a great response from our distributors and retailers that are interested in this product.

Great, thanks guys. Apologies for the bad line.

No, no, no problem. Thank you, Owen.

Thank you. Next question is coming from Frederico Gomes from ATB Capital Markets. Your line is now live.

Hi, thanks for the question. Just a follow-up on Germany. Given the increased demand that you mentioned there, can you just comment on what you're seeing on the supply side? Is there enough product there to serve that market as demand grows? And in terms of pricing, are you seeing any sort of increase there? Thanks.

So, no problem. Basically, what we're seeing in terms of supply, so in essence, product seems to be selling as soon as it comes into the market. Not only—what I'm hearing—not only on our product, but also in terms of product from other competitors in the market. It does not feel as if the market is saturated at all at this point. And so in essence, I think there's still definitely room for additional supply in medical cannabis into the market. And when I say that, I mean mostly on whole flower. The extract market is growing at a slower pace, whereas the patient-led whole flower side of the market is growing at a faster pace. And so, what we see is the market will probably enter a segmented approach looking at premium mainstream products and value products. You'll start to see more, I think, segmentation come through the market as there's more proliferation in terms of product quality. And we will look to participate in all the various parts of that segment in the market. So we're pretty excited about it.

Thanks for that. And then my second question, is just on your organic growth guidance. Could you just maybe provide a bit more color in terms of your segments? Is there any specific segment that you expect will be responsible for most of that organic growth? Thanks.

And just in that organic growth number, a big part of our business, there's no organic growth that we're kind of looking from in our CC Pharma. If anything, what we're looking there is margin growth and cash flow. But it's just a smaller business in regards to our wellness growth we're looking for same growth last year. But we're looking at double-digit growth coming out of both our cannabis and our beer business—our beverage businesses— and that's where the big growth is. Low to mid-single growth on wellness, no growth really coming from our CC Pharma—our medical distribution business.

Thank you very much.

Thank you.

Thank you. We reached the end of our question-and-answer session. I'd like to turn the floor back over to Irwin for any further or closing comments.

Well, thank you, everybody, for joining us on this summer day. Listen, we've had a lot of good stuff reported today, record sales. And if I look back to 2019, at being a $50 million business and this year, we have guidance out there between $950 million to $1 billion. And that is without anything happening in the U.S. So in terms of this guidance includes anything in regards to rescheduling in the U.S., anything that happens in the U.S. And over the last five years, everybody kept asking me, what's happening in the U.S., a lot of things have changed within Tilray. If something happens in the U.S., we're excited about the opportunities in Germany in regards to even the change in selling more and more infused drinks in the U.S. could change dramatically. We've had to deal with the higher excise tax in Canada, and we've had to deal with higher costs because of cannabis issues in regard to insurance and IT costs and protecting ourselves. But this is a team that's made sure we could overcome that in other ways. So one of the things as companies look today is leverage. And as we sit today with 1.7 times leverage, and that we're able to pay $300 million of our subordinate debt last year between our cash flow and just using equity is something to be very, very proud of. So over the last 5 years, we have built something pretty exciting, a lifestyle company that's focused on cannabis, which is cannibalizing alcohol, of course. We have a really exciting craft beer business, and we think there's a lot of growth in the craft beer business. We think there's a lot of growth in the beverage business. We think there's a lot of growth in the spirits business and our wellness business. I think Europe is just beginning, and we're well positioned with two facilities, one in Germany, and now for the first time, we can supply the whole market from the facility, whereas before we could only supply the German government. We have an incredible facility that's working with our Canadian facility in regards to growth. And with that, you're going to see a lot of opportunities. There's going to be growth in many other countries within Europe. You heard me talk about genetics and our genetics bank, and the quality. The thing is, the cannabis user today is becoming more and more educated about potency, the genetics, and what they're using. The cannabis consumer today is just not Gen Z and millennials; it's an older generation that's looking at cannabis for pain, sleep, anxiety, cancer patients, and treating epilepsy among other uses. So cannabis is just not a relaxation product; it's a product for a lot of medical reasons as well as relaxation. As we talk about bringing people together for exciting times, Tilray will continue to evolve into a lifestyle company. As we look at growing this business and I'm sure what's going to happen in the U.S., we look at other categories and what we should expand into as we go through our strategic plans—we've identified what that lifestyle opportunity is for us within the Tilray brands. As you said—as I said before, over 40 brands within this company, and that is since 2019—we produce over 90% of our products. We have over 2,500 dedicated employees that are really dedicated and very lucky to work with this team. We have a great Board of governance that is focused on our ESG and good governance. Last but not least, I want to thank every shareholder out there for being loyal and patient with us. With that, enjoy the rest of your summer. Thank you very much for joining us and enjoy one of our great products.

Thank you. That does conclude today's teleconference. You may disconnect your lines at this time, and have a wonderful day. We thank you for your participation today.